Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

News SummaryMost relevantAll newsSector newsTweets 

CVS Health : Today's Research Reports on Stocks to Watch: CVS Health and Walgreens Boots Alliance

share with twitter share with LinkedIn share with facebook
share via e-mail
06/19/2017 | 02:05pm CEST

NEW YORK, NY / ACCESSWIRE / June 19, 2017 / Even pharmacy chains like CVS Health Corp.'s and Walgreens Boots Alliance's shares were shaky after Amazon announced its deal to acquire Whole Foods. Grocery stores and pharmacy chains were feeling the pressure after Friday's big announcement. Despite the acquisition not directly affecting CVS nor Walgreens, the two stocks saw shares drop as investors cautiously wait to see if there will be any potential threat. It also doesn't help that a CNBC report back in May had indicated that Amazon may also be interesting in launching its own delivery and online pharmacy business.

RDI Initiates Coverage on:

CVS Health Corporation

Walgreens Boots Alliance, Inc.

CVS Health Corporation's (NYSE: CVS) shares closed down 3.78% on Friday on trading volume more than twice as large as usual. CVS was among other pharmacy stocks to drop after Amazon announced it was buying Whole Foods. Traders now may have reason to worry that the online retail giant may be choosing pharmaceutical sales as the next thing to break into. CVS also recently reported a 4.7% decrease in same-store sales in its Q1 report which was not that assuring for traders. In other news the company did announce that in partnership with Drug Store News and Mack Elevation, it will hold an innovation summit that brings together leaders from major healthcare, technology and consumer brands including Facebook, Under Armour, Google and IBM. The summit will be for a discussion about emerging trends that are helping reshape the health care industry.

Access RDI's CVS Health Research Report at:

Walgreens Boots Alliance, Inc.'s shares closed down 4.99% on Friday after the big Amazon news. Plus investors weren't thrilled over some pessimistic updates on its ongoing potential merger with Rite-Aid. The merger has been now in the process for about 1.5 years. A Street.com report indicated that a SEC filing by Rite Aid didn't have an upbeat tone about completing the deal. The Federal Trade Commission is expected to resolve its antitrust review of the merger before July 4th. Chairman Maureen Ohlhausen and Terrell McSweeny are two sitting members that are left who need to vote to challenge the deal before the 7th of next month. If they don't, Walgreens will able to consummate the deal. Traders are eagerly waiting for the FTC's decision.

Access RDI's Walgreens Boots Alliance Research Report at:

Our Actionable Research on CVS Health Corporation (NYSE: CVS) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH
10:54a CVS HEALTH : SXU Featured in CVS Health Report
06/27 CVS HEALTH : Today's Research Reports on Stocks to Watch: Rite Aid and CVS Healt..
06/23 CVS HEALTH : appeals to the City Council in its effort to move into Laguna Drug ..
06/21 CVS HEALTH : Points of Light Recognizes CVS Health As One Of The 50 Most Communi..
06/21 CVS : Experts Discuss How Medicaid Innovations Reduce Costs and Increase Access ..
06/21 CVS HEALTH : Monroe County's tax battle with CVS not over
06/19 CVS HEALTH : Today's Research Reports on Stocks to Watch: CVS Health and Walgree..
06/16 CVS : By the Numbers: Real-World Impact of Rising Drug Costs
06/15 CVS HEALTH : Pharmacy Now Using Time Delay Safes in Ohio for Controlled Substanc..
06/14 CVS HEALTH : Medicaid as a Driver of Care Innovation
More news
Sector news : Drug Retailers - NEC
06/22DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens to Settle -- WSJ
06/21DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens Reach Deal to Settle Lawsuit--Upd..
06/21 STADA ARZNEIMITTEL : Low acceptances leave Stada bid down to the wire
06/21DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens Reach Deal to Settle Lawsuit
06/20 U.S. Supreme Court again limits where companies can be sued
More sector news : Drug Retailers - NEC
News from SeekingAlpha
06/27 WALGREENS/CVS : Good Free-Cash-Flow, But Now In Amazon's Sights
06/26 How To Beat XLP For The Active Investor
06/26 Smart Beta Dividend Growth Stocks
06/26 Sifting Through The Retail Wreck
06/23 The MnM Portfolio, June 2017 Supplement - How Amazon-Proof Is The Portfolio?
Financials ($)
Sales 2017 184 164 M
EBIT 2017 10 168 M
Net income 2017 5 376 M
Debt 2017 24 614 M
Yield 2017 2,45%
P/E ratio 2017 15,60
P/E ratio 2018 13,84
EV / Sales 2017 0,58x
EV / Sales 2018 0,55x
Capitalization 82 003 M
More Financials
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 87,1 $
Spread / Average Target 8,2%
Consensus details
EPS Revisions
More Estimates Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH2.00%82 003
More Results